Grail, Inc., was incorporated in Delaware on September 11, 2015. The company is a healthcare company dedicated to saving lives and improving health by pioneering new technologies for early detection of cancer. The company has built a multidisciplinary organization of scientists, engineers and physicians that is leveraging the power of next generation sequencing (NGS), population-scale clinical research, and state-of-the-art computer science and data science to overcome one of medicine's greatest challenges. Using the company's platform technology, the company has developed a multi-cancer early detection blood test, which has demonstrated in clinical studies that more than 50 cancer types can be detected from a single blood draw and can highly accurately locate cancer signals. 

Expected P&L on Expiry

Key Stats

Pricing Model

About GRAL20260918C70